---
title: "FOSUN PHARMA's subsidiary FOSUN PHARMA Industry plans to participate in the establishment of a private equity investment fund"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/263059772.md"
description: "FOSUN PHARMA's subsidiary FOSUN PHARMA Industry has signed a partnership agreement with 11 investors, planning to invest 100 million yuan to establish a private equity investment fund. The fund will invest in strategic emerging fields such as chemical innovative drugs, biological drugs, and high-end medical devices, aiming to leverage the strengths of all parties to expand its layout in innovative drugs and biological drugs, and to achieve investment returns"
datetime: "2025-10-28T10:41:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263059772.md)
  - [en](https://longbridge.com/en/news/263059772.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263059772.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/263059772.md) | [繁體中文](https://longbridge.com/zh-HK/news/263059772.md)


# FOSUN PHARMA's subsidiary FOSUN PHARMA Industry plans to participate in the establishment of a private equity investment fund

According to the announcement from Fosun Pharma (02196), on October 28, 2025, the company's controlling subsidiary, Fosun Pharma Industry, signed a "Partnership Agreement" with 11 other investors, intending to contribute RMB 100 million as an LP cash investment to establish a target fund. The target fund will primarily invest in enterprises in strategic emerging sub-sectors such as chemical innovative drugs, biological drugs (including vaccines), high-end medical devices (including IVD), traditional Chinese medicine supplements, and synthetic biology.

This investment aims to fully leverage the advantages of the Group and China Resources Pharmaceutical in the health sector, and in conjunction with local industrial policies and location advantages in Chengdu, actively expand the Group's channels for layout in innovative drugs, biological drugs, high-end medical devices, synthetic biology, and other strategic emerging fields to achieve investment returns.

Once established, the target fund will become an associate company of the Group

### 相关股票

- [FOSUN PHARMA (600196.CN)](https://longbridge.com/zh-CN/quote/600196.CN.md)
- [FOSUN PHARMA (02196.HK)](https://longbridge.com/zh-CN/quote/02196.HK.md)

## 相关资讯与研究

- [Fosun Pharma Sets March 2026 Board Meeting to Approve 2025 Results and Dividend Plan](https://longbridge.com/zh-CN/news/278366476.md)
- [A Look At Fosun International (SEHK:656) Valuation After Recent Mixed Share Price Performance](https://longbridge.com/zh-CN/news/281035263.md)
- [Starfighters Space Delays Annual 10-K Filing](https://longbridge.com/zh-CN/news/281397627.md)
- [TSMC's Supply Squeeze Through 2028 Could Be This Chipmaker's Big Break As AI Demand From Nvidia, Apple Surges](https://longbridge.com/zh-CN/news/281141442.md)
- [Defence push quadruples with latest DAC approvals, execution to now be in focus](https://longbridge.com/zh-CN/news/281470473.md)